• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    $6.9M Bet On This Healthcare Stock? Check Out These 4 Stocks Insiders Are Buying

    12/19/23 6:59:41 AM ET
    $CHWY
    $OLMA
    $TSE
    $WFCF
    Catalog/Specialty Distribution
    Consumer Discretionary
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $CHWY alert in real time by email

    Although U.S. stocks closed mostly higher on Monday, there were a few notable insider trades.

    When insiders purchase shares, it indicates their confidence in the company's prospects or that they view the stock as a bargain. Either way, this signals an opportunity to go long on the stock. Insider purchases should not be taken as the only indicator for making an investment or trading decision. At best, it can lend conviction to a buying decision.

    Below is a look at a few recent notable insider purchases. For more, check out Benzinga's insider transactions platform.

    Olema Pharmaceuticals

    • The Trade: Olema Pharmaceuticals, Inc. (NASDAQ:OLMA) Director Graham Walsmley acquired a total of 640,000 shares an average price of $10.74. To acquire these shares, it cost around $6.87 million.
    • What’s Happening: Olema Pharmaceuticals recently announced interim results from an ongoing Phase 1b/2 clinical study of palazestrant in combination with CDK4/6 inhibitor ribociclib.
    • What Olema Pharmaceuticals Does: Olema Pharmaceuticals inc is a clinical-stage biopharmaceutical company. It is focused on the discovery, development, and commercialization of next generation targeted therapies for women's cancers.

    Trinseo

    • The Trade: Trinseo PLC (NYSE:TSE) Director Matthew Farrell acquired a total of 50,000 shares at an average price of $7.21. To acquire these shares, it cost around $360,500.
    • What’s Happening: On Nov. 3, Trinseo posted downbeat quarterly results.
    • What Trinseo Does: Trinseo PLC is a leading global materials company and manufacturer of latex and plastics products.

    Don’t forget to check out our premarket coverage here

    Where Food Comes From

    • The Trade: Where Food Comes From, Inc. (NASDAQ:WFCF) Director Pete Lapaseotes bought a total of 1,438 shares at an average price of $12.75. To acquire these shares, it cost around $18,334.
    • What’s Happening: On Nov. 9, Where Food Comes From posted third-quarter EPS of 13 cents.
    • What Where Food Comes From Does: Where Food Comes From Inc is a third-party food verification company. It offers food production audits and uses verification processes to ensure that claims made by food producers and processors are accurate.

    Chewy

    • The Trade: Chewy, Inc. (NYSE:CHWY) Director James A Star bought a total of 12,242 shares at an average price of $20.38. The insider spent around $249,519 to buy those shares.
    • What’s Happening: The FDA recently issued warning letters to Chewy and eight other companies for violating federal law by distributing or manufacturing unapproved and misbranded antimicrobial animal drugs for animals that could potentially give rise to drug-resistant superbugs.
    • What Chewy Does: Chewy is the largest e-commerce pet care retailer in the U.S., generating $10.1 billion in 2022 sales across pet food, treats, hard goods, and pharmacy categories.

     

    Check This Out: FedEx Likely To Report Higher Q2 Earnings; These Most Accurate Analysts Revise Forecasts Ahead Of Earnings Call

    Get the next $CHWY alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $CHWY
    $OLMA
    $TSE
    $WFCF

    CompanyDatePrice TargetRatingAnalyst
    Olema Pharmaceuticals Inc.
    $OLMA
    3/27/2026Peer Perform
    Wolfe Research
    Olema Pharmaceuticals Inc.
    $OLMA
    3/19/2026Buy
    Jefferies
    Chewy Inc.
    $CHWY
    2/19/2026$28.00Mkt Perform → Outperform
    Raymond James
    Olema Pharmaceuticals Inc.
    $OLMA
    2/11/2026$48.00Buy
    Stifel
    Olema Pharmaceuticals Inc.
    $OLMA
    1/7/2026$40.00Overweight
    Piper Sandler
    Trinseo PLC
    $TSE
    12/1/2025Overweight → Neutral
    Alembic Global Advisors
    Olema Pharmaceuticals Inc.
    $OLMA
    10/8/2025$20.00Buy
    Guggenheim
    Chewy Inc.
    $CHWY
    9/25/2025$48.00Neutral → Buy
    MoffettNathanson
    More analyst ratings

    $CHWY
    $OLMA
    $TSE
    $WFCF
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    December 14, 2023 - FDA Warns Nine Manufacturers, Distributors of Unapproved Antimicrobials for Animals

    For Immediate Release: December 14, 2023 Today, the U.S. Food and Drug Administration is announcing the issuance of nine warning letters to manufacturers and distributors of unapproved and misbranded antimicrobial animal drugs for violations of federal law. The agency is concerned because these products contain antimicrobials that are important in human medicine and using them without medical oversight contribut

    12/14/23 9:00:20 AM ET
    $CHWY
    Catalog/Specialty Distribution
    Consumer Discretionary

    $CHWY
    $OLMA
    $TSE
    $WFCF
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Olema Oncology Announces Preclinical Data for Palazestrant and OP-3136 at the 2026 AACR Annual Meeting

    Palazestrant's mechanism of action confirmed; full recruitment of corepressor protein NCoR1 enables complete antagonism of the estrogen receptorOP-3136, in combination with palazestrant, exhibits synergistic anti-tumor activity in ER+/HER2- breast cancer models driven by suppression of cell-cycle and estrogen receptor-driven oncogenic signalingPalazestrant is currently being evaluated in two Phase 3 clinical trials; OP-3136 is enrolling patients in the ongoing Phase 1 study SAN FRANCISCO, April 17, 2026 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (("Olema" or "Olema Oncology", NASDAQ:OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercia

    4/17/26 4:01:00 PM ET
    $OLMA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chewy to Acquire Modern Animal Accelerating Evolution to a Fully Integrated Healthcare Ecosystem

    Chewy, Inc. (NYSE:CHWY) ("Chewy"), today announced it has entered into a definitive agreement to acquire Modern Animal, Inc. ("Modern Animal"), a technology-forward veterinary platform with 29 owned clinics, 24/7 virtual care, and a high-retention membership model. This acquisition represents an important strategic step in Chewy's evolution into a fully integrated pet healthcare ecosystem, combining care, commerce and services across the pet lifecycle. Modern Animal adds a scaled, tech-enabled in-person care model that accelerates Chewy's clinic expansion and complements its existing health, pharmacy and Chewy Vet Care ("CVC") capabilities. The acquisition is expected to add over $125 mil

    4/8/26 9:00:00 AM ET
    $CHWY
    Catalog/Specialty Distribution
    Consumer Discretionary

    Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

    SAN FRANCISCO, April 02, 2026 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (("Olema" or "Olema Oncology", NASDAQ:OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies for breast cancer and beyond, today announced that the Company granted stock options to four new employees to purchase an aggregate of 188,500 shares of the Company's common stock, effective as of April 1, 2026. These awards were approved by the Compensation Committee of Olema's Board of Directors and granted under the Company's 2022 Inducement Plan as an inducement material to the new employees entering into employment with Olema, in accordance

    4/2/26 4:30:00 PM ET
    $OLMA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CHWY
    $OLMA
    $TSE
    $WFCF
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Wolfe Research initiated coverage on Olema Pharmaceuticals

    Wolfe Research initiated coverage of Olema Pharmaceuticals with a rating of Peer Perform

    3/27/26 8:52:12 AM ET
    $OLMA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Jefferies resumed coverage on Olema Pharmaceuticals

    Jefferies resumed coverage of Olema Pharmaceuticals with a rating of Buy

    3/19/26 8:27:01 AM ET
    $OLMA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chewy upgraded by Raymond James with a new price target

    Raymond James upgraded Chewy from Mkt Perform to Outperform and set a new price target of $28.00

    2/19/26 7:46:41 AM ET
    $CHWY
    Catalog/Specialty Distribution
    Consumer Discretionary

    $CHWY
    $OLMA
    $TSE
    $WFCF
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Billings William G.

    4 - Chewy, Inc. (0001766502) (Issuer)

    4/10/26 4:08:52 PM ET
    $CHWY
    Catalog/Specialty Distribution
    Consumer Discretionary

    SEC Form 4 filed by Hu Da-Wai

    4 - Chewy, Inc. (0001766502) (Issuer)

    4/10/26 4:07:57 PM ET
    $CHWY
    Catalog/Specialty Distribution
    Consumer Discretionary

    SEC Form 4 filed by Deppe Christopher S.

    4 - Chewy, Inc. (0001766502) (Issuer)

    4/10/26 4:07:04 PM ET
    $CHWY
    Catalog/Specialty Distribution
    Consumer Discretionary

    $CHWY
    $OLMA
    $TSE
    $WFCF
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Farrell Matthew bought $240,028 worth of Ordinary Shares (100,000 units at $2.40), increasing direct ownership by 67% to 250,225 units (SEC Form 4)

    4 - Trinseo PLC (0001519061) (Issuer)

    8/14/25 5:43:10 PM ET
    $TSE
    Major Chemicals
    Industrials

    COO Saunders Leann bought $12,510 worth of shares (1,750 units at $7.15) (SEC Form 4)

    4 - Where Food Comes From, Inc. (0001360565) (Issuer)

    5/21/25 3:26:31 PM ET
    $WFCF
    Computer Software: Prepackaged Software
    Technology

    CEO Saunders John K bought $12,510 worth of shares (1,750 units at $7.15) (SEC Form 4)

    4 - Where Food Comes From, Inc. (0001360565) (Issuer)

    5/21/25 3:26:10 PM ET
    $WFCF
    Computer Software: Prepackaged Software
    Technology

    $CHWY
    $OLMA
    $TSE
    $WFCF
    SEC Filings

    View All

    SEC Form 8-K filed by Where Food Comes From Inc.

    8-K - Where Food Comes From, Inc. (0001360565) (Filer)

    4/9/26 7:27:43 PM ET
    $WFCF
    Computer Software: Prepackaged Software
    Technology

    SEC Form 8-K filed by Chewy Inc.

    8-K - Chewy, Inc. (0001766502) (Filer)

    4/8/26 9:08:13 AM ET
    $CHWY
    Catalog/Specialty Distribution
    Consumer Discretionary

    Amendment: SEC Form 10-K/A filed by Where Food Comes From Inc.

    10-K/A - Where Food Comes From, Inc. (0001360565) (Filer)

    4/6/26 11:00:20 AM ET
    $WFCF
    Computer Software: Prepackaged Software
    Technology

    $CHWY
    $OLMA
    $TSE
    $WFCF
    Leadership Updates

    Live Leadership Updates

    View All

    Chewy Appoints Chris Deppe as Chief Financial Officer

    Chewy, Inc. (NYSE:CHWY) ("Chewy"), a leading and trusted destination for pet parents and partners everywhere, announced today the appointment of Chris Deppe as Chief Financial Officer (CFO). Deppe is a seasoned finance and operations leader with more than 20 years of experience. He joined Chewy in 2022 as the Vice President of Supply Chain and Operations Finance, and most recently served as the Head of all Corporate and Commercial Finance Functions. During his tenure, he has played a key role in advancing the company's financial strategy, enhancing operational rigor, and supporting strong business performance aligned with Chewy's long-term strategic priorities. Prior to joining Chewy, D

    2/24/26 9:00:00 AM ET
    $CHWY
    Catalog/Specialty Distribution
    Consumer Discretionary

    Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

    SAN FRANCISCO, March 04, 2025 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (("Olema" or "Olema Oncology", NASDAQ:OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies for breast cancer and beyond, today announced that the Company granted stock options to two new employees to purchase an aggregate of 19,800 shares of the Company's common stock, effective as of March 3, 2025. These awards were approved by the Compensation Committee of Olema's Board of Directors and granted under the Company's 2022 Inducement Plan as an inducement material to the new employees entering into employment with Olema, in accordance w

    3/4/25 4:30:00 PM ET
    $OLMA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Olema Oncology Appoints Shawnte M. Mitchell, J.D. as Chief Legal Officer and Corporate Secretary

    SAN FRANCISCO, Feb. 18, 2025 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (("Olema" or "Olema Oncology", NASDAQ:OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies for breast cancer and beyond, today announced the appointment of Shawnte M. Mitchell, J.D., as Chief Legal Officer and Corporate Secretary. "We are pleased to welcome Shawnte to our executive team to lead our Legal function as we progress both our late-stage palazestrant programs and our OP-3136 KAT6 program through clinical development," said Sean P. Bohen, M.D., Ph.D., President and Chief Executive Officer of Olema Oncology. "Her extensive e

    2/18/25 7:00:00 AM ET
    $OLMA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CHWY
    $OLMA
    $TSE
    $WFCF
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by Trinseo PLC

    SC 13G - Trinseo PLC (0001519061) (Subject)

    12/17/24 5:11:10 PM ET
    $TSE
    Major Chemicals
    Industrials

    SEC Form SC 13G filed by Olema Pharmaceuticals Inc.

    SC 13G - Olema Pharmaceuticals, Inc. (0001750284) (Subject)

    12/11/24 4:30:15 PM ET
    $OLMA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13D/A filed by Olema Pharmaceuticals Inc.

    SC 13D/A - Olema Pharmaceuticals, Inc. (0001750284) (Subject)

    12/4/24 7:49:50 PM ET
    $OLMA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CHWY
    $OLMA
    $TSE
    $WFCF
    Financials

    Live finance-specific insights

    View All

    Chewy Announces Fiscal Fourth Quarter and Full Year 2025 Financial Results

    Chewy, Inc. (NYSE:CHWY) ("Chewy"), a trusted destination for pet parents and partners everywhere, has released its financial results for the fiscal fourth quarter and full year 2025 ended February 1, 2026. Fiscal quarter and year ended February 1, 2026 had 13 and 52 weeks, respectively. Fiscal quarter and year ended February 2, 2025 had 14 and 53 weeks, respectively. Year over year results for Fiscal Q4 2025 and Fiscal Year 2025 below compares US GAAP basis results, unless otherwise normalized for 13-weeks or 52-weeks pro-rata. Fiscal 2025 Results: Net sales of $12.60 billion improved 6.2 percent year over year or 8.3 percent on a normalized 52-week basis Gross margin of 29.8 perc

    3/25/26 7:05:00 AM ET
    $CHWY
    Catalog/Specialty Distribution
    Consumer Discretionary

    Trinseo Reports Fourth Quarter and Full-Year 2025 Financial Results

    Fourth Quarter 2025 Highlights Cash provided by operations of $23 million and capital expenditures of $16 million resulted in Free Cash Flow* of $7 million and ending cash of $149 million (of which $2 million was restricted) and total liquidity of $334 million Net loss of $251 million and EPS of $(6.98) included pre-tax restructuring and other charges of $127 million related mainly to the previously announced closures the virgin MMA production and ACH operations at our facilities in Italy and the polystyrene assets in Germany Adjusted EBITDA* of $26 million included $6 million of unfavorable net timing and negative equity income from Americas Styrenics due to lower margins, partial

    3/13/26 11:05:00 AM ET
    $TSE
    Major Chemicals
    Industrials

    Chewy Announces Fiscal Fourth Quarter and Full Year 2025 Financial Results Conference Call

    Chewy, Inc. (NYSE:CHWY) ("Chewy"), a trusted destination for pet parents and partners everywhere, announced today that it will report fiscal fourth quarter and full year 2025 financial results before the market opens on Wednesday, March 25, 2026. Management will host a conference call and webcast to discuss the company's financial results at 8:00 am ET. To access the conference call by phone, please visit this link for registration (Phone Registration Link) to be provided with dial in details, including a unique PIN to access the conference call. To avoid delays, we encourage participants to register in advance or at a minimum 15 minutes before the start of the call. A live audio webcas

    3/2/26 7:30:00 AM ET
    $CHWY
    Catalog/Specialty Distribution
    Consumer Discretionary